Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells

Area of Science:

• Immunology
• Nanotechnology
• Oncology

Background:

• mRNA cancer vaccines show promise but face challenges due to tumor heterogeneity.
• Current lipid nanoparticle (LNP) delivery systems primarily target dendritic cells (DCs), potentially missing tumor clones with varying antigen expression.
• Tumor immune escape remains a significant hurdle for effective cancer vaccination.

Purpose of the Study:

• To develop a dual-targeted LNP strategy for enhanced antigen presentation in both DCs and tumor cells.
• To overcome limitations of current mRNA vaccines in addressing tumor heterogeneity and immune escape.
• To improve the efficacy of mRNA cancer vaccines through simultaneous targeting of antigen-presenting cells and tumor cells.

Main Methods:

• Functionalization of LNPs with DEC-205-targeting antibodies (dLNPs) via fusion with apolipoprotein A1 (ApoA1) for dual targeting.
• Intravenous administration of dLNPs carrying antigen-encoding mRNA and toll-like receptor (TLR) agonists.
• Evaluation of dLNP accumulation in lymph nodes and tumors, antigen presentation in DCs and tumor cells, and CD8+ T cell responses.

Main Results:

• dLNPs selectively accumulated in lymph nodes and tumors post-administration.
• Co-delivery of mRNA and TLR agonists via dLNPs significantly enhanced antigen presentation in both DCs and tumor cells.
• Robust CD8+ T cell responses and potent antitumor effects were observed without systemic toxicity.

Conclusions:

• The dual-targeting LNP strategy effectively enhances antigen presentation and T cell responses against heterogeneous tumors.
• This approach demonstrates potential for overcoming immune escape mechanisms in cancer.
• The developed dLNPs offer a promising platform for improving mRNA cancer vaccine efficacy and safety.